Life Edit uses its proprietary gene editing platform to develop new editing systems, research projects, and therapeutic assets. We are looking to form strategic partnerships with biotechnology and biopharmaceutical companies to advance their life-changing and curative therapies.
Our flexible partnership options span non-exclusive licensing of our gene editing systems, exclusive licenses to assets, and collaborations as starting points for strategic partnerships with pharma and leading biotech companies.
Our gene editing platform offers one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors that provide flexible editing, both in vivo and ex vivo, and unprecedented access to the genome. Our gene editing systems are available to license non-exclusively for enablement of ex vivo cell therapies as well as exclusively through R&D collaborations for in vivo therapeutic development.
Our gene editing tools were developed using a proprietary collection of non-pathogenic microbes.
Large and diverse library of RNA-guided nucleases including Type II and Type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of our proprietary deaminases, as well as next generation gene editing platforms
Several classes of DNA modifying enzymes, including novel deaminases for cytidine (C) or adenine (A) base editing
Our lead RGNs show activity in vivo and are deliverable through multiple delivery technologies
Our platform enables ex vivo engineering for cell therapies and regenerative medicines
Our nuclease collection has a broad range of Protospacer Adjacent Motifs (PAMs) which offer unprecedented access to genomes
Life Edit is part of the ElevateBio ecosystem of enabling technologies and end-to-end capabilities dedicated to creating transformative cell and gene therapies. In addition to our next-generation gene editing capabilities, our partners have the opportunity to access ElevateBio’s other Enabling Technologies, inclusive of induced pluripotent stem cells (iPSC) and cell, vector, and protein engineering; process development and cGMP manufacturing through BaseCamp; and R&D and regulatory expertise from its highly-talented team of cell and gene therapy industry leaders.